MRNA technology has saved millions of lives through the swift rollout of COVID-19 vaccines from the likes of Moderna and Pfizer. Now, I-Mab wants to replicate that success on a quest to treat cancer.

I-Mab (NASDAQ:IMAB) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals (NASDAQ:TCON) related to a collaboration agreement but the company would have to pay part of Tracon's ...

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over ...

I-Mab has had a big 12 months, landing an $180 million upfront from AbbVie and delivering a series of readouts from clinical trials. Now, the Chinese biotech is reportedly seeking to build on its ...

ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

Having first emerged as therapeutics in the 1980s, monoclonal antibodies (mAbs) are the predominant class of recombinant biologic drugs in development. While intravenous (IV) infusion is a frequently ...

I-Mab announced positive results from a Phase 1b study of its bispecific antibody, givastomig, which targets Claudin 18.2 and 4-1BB for treating Claudin 18.2-positive gastric cancers. The study, ...

Monoclonal antibody (mAb)-based therapeutics are emerging as one of the fastest-growing categories of drugs being developed today. In fact, according to a recent analysis, 1 the market for mAbs has ...

MAINZ, Germany & MUNICH--(BUSINESS WIRE)--BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of ...